A new Scientific Reports study adds an important nuance to the long COVID conversation. The biggest difference was not between people with PCC and without PCC, but between uninfected people and everyone who had recovered from SARS2🧵
Long COVID may be part of a broader post-infectious biological spectrum, where symptomatic PCC represents the more clinically visible end of a continuous dysregulation rather than a completely separate category.
That matters, because a lot of people still think in very rigid categories here. But instead of two clean boxes - recovered vs long COVID - the biology may look more like a continuum.
The study looked at plasma proteins 3 months after mild, non hospitalized COVID-19. The cohort included 35 uninfected controls, 62 convalescent individuals without PCC, and 53 people with PCC.
What they found is striking. People who had COVID still showed a distinct plasma proteome compared with uninfected controls at 3 months. But PCC and convalescent participants overlapped a lot.
It may actually be the point. If long COVID is a heterogeneous post-infectious syndrome, overlap is exactly what you would expect.
In that framework, PCC may not be a totally separate biological state. It may be the more symptomatic, more clinically apparent end of a shared post-infectious process.
The oxidative stress findings fit that model well. Both post-infection groups had lower glutathione (GSH) than uninfected controls, suggesting reduced antioxidant reserve even outside overt PCC.
But the PCC group showed stronger signs of ongoing redox stress, including lower PRDX6, higher PON3 and VNN1, and higher 8-OHdG, a marker of oxidative DNA damage.
So this does not look like some people have biology, others just have symptoms. It looks more like a shared post-infectious shift, with symptom burden emerging where that dysregulation is stronger, more persistent, or less well compensated.
The study also found signals in complement, coagulation, inflammation, and metabolic pathways - including CPB2, C1Q, KNG1, GAPDH, CST3, and PCSK9. That adds to the case that long COVID has a real systemic biological footprint.
Reason to be cautious. ELISA validation was only partly consistent with the proteomics. Several markers were not robustly replicated across methods.
Real value of this study is not a ready-made biomarker, but broader idea - post COVID biology may persist even in people who do not currently meet criteria for PCC, while symptomatic PCC may reflect the more clinically visible edge of that same continuum. @szupraha @ZdravkoOnline @adamvojtech86
That also means the overlap between PCC and convalescent groups should not automatically be dismissed as noise. It may reflect the reality of a dynamic, layered, post infectious syndrome rather than a clean binary state.
We need true longitudinal tracking of the same people over time.
Still, this paper is important. Long COVID may be less about crossing a sharp biological line, and more about where someone sits on a post-infectious spectrum of ongoing dysregulation.
Chowdhury at al., Distinct plasma proteome signature at 3 months post-COVID-19 infection irrespective of post-COVID condition. nature.com/articles/s4159…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We now have a complementary study that helps extend the picture. If the first paper suggests post-COVID biology may exist on a spectrum, this second one suggests recovery itself may also be real, prolonged, and only partial.🧵
This was a 2 year longitudinal proteomics study of hospitalized COVID survivors. The researchers profiled plasma at 6 months, 1 year, and 2 years after symptom onset and compared it with matched healthy controls.
This cohort was infected in the very early 2020 wave.
A new study asks a deceptively simple question - is Long COVID just a slower recovery, or is it a persistent immune disorder? Their data point toward the latter !🧵
For this single-cell analysis, the authors selected 9 women from a prospective cohort of patients hospitalized with COVID-19. Blood was collected during acute infection, at 3 months, and again 18-24 months later. Some recovered without long-term complications. Others developed pulmonary or cardiovascular Long COVID.
What makes the paper valuable is not the size of the cohort, but the depth of follow up. The authors profiled peripheral blood mononuclear cells at single-cell resolution and tracked how immune states evolved over time.
A new first trimester study makes an important point. Even when direct detection of SARS-CoV-2 in placental tissue is minimal, the early maternal-fetal environment can still be meaningfully disrupted - immunologically and developmentally🧵
Biological harm does not have to depend on heavy, obvious viral presence inside the tissue itself.
In this study, the authors analyzed a large cohort of 761 first trimester pregnancies. They found only very limited signs of viral RNA in villous and decidual tissue, and no sample was convincingly positive across the main viral targets. That argues against frequent, efficient placental infection.
Very small study, but a genuinely interesting one on long COVID.
After reinfection, the biology did not simply replay the first infection - and in this cohort, the booster did not worsen the measured inflammatory/neurology protein profile🧵
The authors measured 182 inflammatory and neurology related proteins in plasma - 6-9 months after primary infection
after a booster
after breakthrough infection.
In a subset, they had longitudinal samples at 3 timepoints, which makes the paper much more interesting than a simple one time comparison.
It’s small, exploratory, and more hypothesis generating study.
But it asks a very good question.
COVID-19 is not just a story of inflammation. This review argues that it is also a story about what SARS2 does to mitochondria - and how that can turn infection into energy failure, cell injury, and worse oxygenation. This is an important mechanistic review🧵
Mitochondria are not framed here as passive bystanders damaged late in severe illness. In this model, they are active participants in disease - they shape ATP production, ROS, apoptosis, and oxygen sensing.
The review describes two main routes of damage -
very early changes in expression of mito-related genes (hours)
direct interactions between viral proteins and host mito proteins.
So not just the cell is stressed, but a more specific viral rewiring of core cell machinery.
This interesting paper lays out a very specific idea for how severe COVID-19 may be driven not only by the virus itself, but by the way the immune system handles what the virus leaves behind🧵
The starting point is simple.
SARS2 can leave behind viral RNA and nucleocapsid protein (N). N naturally binds viral RNA, and during infection people also make antibodies against N.
The authors build the story from there.
Viral RNA + nucleocapsid (N) + anti-N IgG
= an immune complex carrying viral genetic material.